| Hiroshi Yamasaki, MD | |
|
25195 Kelly Rd, Suite A, Roseville, MI 48066-4909 | |
| (586) 775-4594 | |
| (586) 775-4506 |
| Full Name | Hiroshi Yamasaki |
|---|---|
| Gender | Male |
| Speciality | Interventional Cardiology |
| Experience | 35 Years |
| Location | 25195 Kelly Rd, Roseville, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538161187 | NPI | - | NPPES |
| 060 500 8831 | Other | MI | BLUE CROSS BLUE SHEILD |
| 4129307 | Medicaid | MI | |
| OH-26467011 | Other | MI | MEDICARE ID |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ascension St John Hospital | Detroit, MI | Hospital |
| Ascension Macomb Oakland Hosp-warren Campus | Warren, MI | Hospital |
| Beaumont Hospital - Grosse Pointe | Grosse pointe, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ascension St John Hospital | 3173424082 | 296 |
| Ascension Macomb Oakland Hospital | 7315859725 | 121 |
News Archive
The National Institute of Standards and Technology (NIST) has developed prototype calibration tools for an experimental medical imaging technique that offers new advantages in diagnosing and monitoring of certain cancers and possibly other medical conditions.
Weill Cornell Medicine has received a $1.27 million grant from the United States Department of Defense (DoD) to develop treatment for a rare but devastating eye condition largely affecting military personnel who suffer traumatic eye injuries in combat.
Patients with trauma, stroke, heart attack and respiratory failure who were transported by basic life support (BLS) ambulances had a better chance of survival than patients who were transported by advanced life support (ALS) ambulances, a study of Medicare patients in urban counties nationwide found.
Iverson Genetic Diagnostics today announced the company has received approval from CMS to conduct a WARFARIN Clinical Study. The two-year (2) study will assess the impact of genetic information in calculating doses and the changes in the rate of adverse events when initiating Warfarin drug therapy. These changes will be compared against doses initiated without genetic data. The randomized and blinded, multi-center study will involve more than 7000 participants at over 50 sites nationwide.
› Verified 2 days ago
| Entity Name | Ascension Macomb Oakland Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518124320 PECOS PAC ID: 7315859725 Enrollment ID: O20031104000571 |
News Archive
The National Institute of Standards and Technology (NIST) has developed prototype calibration tools for an experimental medical imaging technique that offers new advantages in diagnosing and monitoring of certain cancers and possibly other medical conditions.
Weill Cornell Medicine has received a $1.27 million grant from the United States Department of Defense (DoD) to develop treatment for a rare but devastating eye condition largely affecting military personnel who suffer traumatic eye injuries in combat.
Patients with trauma, stroke, heart attack and respiratory failure who were transported by basic life support (BLS) ambulances had a better chance of survival than patients who were transported by advanced life support (ALS) ambulances, a study of Medicare patients in urban counties nationwide found.
Iverson Genetic Diagnostics today announced the company has received approval from CMS to conduct a WARFARIN Clinical Study. The two-year (2) study will assess the impact of genetic information in calculating doses and the changes in the rate of adverse events when initiating Warfarin drug therapy. These changes will be compared against doses initiated without genetic data. The randomized and blinded, multi-center study will involve more than 7000 participants at over 50 sites nationwide.
› Verified 2 days ago
| Entity Name | Ascension Medical Group Michigan |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942317631 PECOS PAC ID: 0648180406 Enrollment ID: O20031113000362 |
News Archive
The National Institute of Standards and Technology (NIST) has developed prototype calibration tools for an experimental medical imaging technique that offers new advantages in diagnosing and monitoring of certain cancers and possibly other medical conditions.
Weill Cornell Medicine has received a $1.27 million grant from the United States Department of Defense (DoD) to develop treatment for a rare but devastating eye condition largely affecting military personnel who suffer traumatic eye injuries in combat.
Patients with trauma, stroke, heart attack and respiratory failure who were transported by basic life support (BLS) ambulances had a better chance of survival than patients who were transported by advanced life support (ALS) ambulances, a study of Medicare patients in urban counties nationwide found.
Iverson Genetic Diagnostics today announced the company has received approval from CMS to conduct a WARFARIN Clinical Study. The two-year (2) study will assess the impact of genetic information in calculating doses and the changes in the rate of adverse events when initiating Warfarin drug therapy. These changes will be compared against doses initiated without genetic data. The randomized and blinded, multi-center study will involve more than 7000 participants at over 50 sites nationwide.
› Verified 2 days ago
| Entity Name | Ascension St John Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043478910 PECOS PAC ID: 3173424082 Enrollment ID: O20040115000409 |
News Archive
The National Institute of Standards and Technology (NIST) has developed prototype calibration tools for an experimental medical imaging technique that offers new advantages in diagnosing and monitoring of certain cancers and possibly other medical conditions.
Weill Cornell Medicine has received a $1.27 million grant from the United States Department of Defense (DoD) to develop treatment for a rare but devastating eye condition largely affecting military personnel who suffer traumatic eye injuries in combat.
Patients with trauma, stroke, heart attack and respiratory failure who were transported by basic life support (BLS) ambulances had a better chance of survival than patients who were transported by advanced life support (ALS) ambulances, a study of Medicare patients in urban counties nationwide found.
Iverson Genetic Diagnostics today announced the company has received approval from CMS to conduct a WARFARIN Clinical Study. The two-year (2) study will assess the impact of genetic information in calculating doses and the changes in the rate of adverse events when initiating Warfarin drug therapy. These changes will be compared against doses initiated without genetic data. The randomized and blinded, multi-center study will involve more than 7000 participants at over 50 sites nationwide.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hiroshi Yamasaki, MD 25195 Kelly Rd, Suite A, Roseville, MI 48066-4909 Ph: (586) 775-4594 | Hiroshi Yamasaki, MD 25195 Kelly Rd, Suite A, Roseville, MI 48066-4909 Ph: (586) 775-4594 |
News Archive
The National Institute of Standards and Technology (NIST) has developed prototype calibration tools for an experimental medical imaging technique that offers new advantages in diagnosing and monitoring of certain cancers and possibly other medical conditions.
Weill Cornell Medicine has received a $1.27 million grant from the United States Department of Defense (DoD) to develop treatment for a rare but devastating eye condition largely affecting military personnel who suffer traumatic eye injuries in combat.
Patients with trauma, stroke, heart attack and respiratory failure who were transported by basic life support (BLS) ambulances had a better chance of survival than patients who were transported by advanced life support (ALS) ambulances, a study of Medicare patients in urban counties nationwide found.
Iverson Genetic Diagnostics today announced the company has received approval from CMS to conduct a WARFARIN Clinical Study. The two-year (2) study will assess the impact of genetic information in calculating doses and the changes in the rate of adverse events when initiating Warfarin drug therapy. These changes will be compared against doses initiated without genetic data. The randomized and blinded, multi-center study will involve more than 7000 participants at over 50 sites nationwide.
› Verified 2 days ago
Robert Lewis Marchese, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 25810 Kelly Rd, Suite 3, Roseville, MI 48066 Phone: 586-777-9724 Fax: 586-777-9725 | |
Benjamin O Osowa, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 18263 E 10 Mile Rd, Suite E, Roseville, MI 48066 Phone: 586-552-8696 Fax: 586-552-4404 | |
Dr. Majid Alzagoum, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 18303 E 10 Mile Rd, Suite 100, Roseville, MI 48066 Phone: 586-776-8877 Fax: 586-776-3092 | |
Dr. Wahed Ishaqsei, M.D. Cardiovascular Disease Medicare: May Accept Medicare Assignments Practice Location: 18263 E 10 Mile Rd, Suite D, Roseville, MI 48066 Phone: 586-778-4950 Fax: 586-778-4952 | |
Dr. Mohamad K. Ajjour, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 18303 E 10 Mile Rd, Suite 100, Roseville, MI 48066 Phone: 586-776-8877 Fax: 586-776-3092 | |
Dr. Ameer Abdulrazzak, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 18001 E 10 Mile, Suite 1, Roseville, MI 48066 Phone: 586-218-5800 Fax: 586-218-5808 | |
Dr. Madjid Mesgarzadeh, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 25910 Kelly Rd, Suite B, Roseville, MI 48066 Phone: 586-772-3366 Fax: 586-772-3355 |